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ABSTRACT
Introduction: Chronic kidney disease (CKD) is common
and carries a high risk of morbidity, including hospital
admissions and readmissions and mortality. This is
largely attributed to an increased risk of cardiovascular
disease. Patients with CKD are less likely to receive
evidence-based treatments for cardiovascular disease.
However, these treatments are based on trials which
generally exclude patients with CKD. It is therefore
unclear whether this patient group derives the same
benefits without an increased risk of adverse effects.
Methods and analysis: The Acute Care QUAliTy in
chronic Kidney disease (ACQUATIK) study is a
prospective, observational, multicentre cohort study.
Over 4000 patients will be recruited with an enrolment
period of 2 years and a follow-up period of 2–4 years.
Patients under follow-up by a renal team will be
excluded. Data will be obtained from patient and
hospital records during the index admission.
Preadmission data will be extracted from general
practice records based on the Quality and Outcomes
Framework. Diagnosis, comorbidities and procedure
data pertaining to the index and subsequent
admissions will be extracted from the Hospital Episode
Statistics database and long-term mortality data will be
tracked using the Office of National Statistics. This
information will allow us to examine a complete patient
journey through primary and secondary care, providing
unequalled levels of information on treatment and
outcomes of patients with CKD. The combined data set
will be used to compare outcomes and treatments
among patients with CKD versus patients without CKD.
The primary end point is hospital readmission rates.
The relationship between age, sex, ethnicity,
socioeconomic status and concurrent comorbidities
will be analysed to determine their influence on
outcomes and treatments.
Ethics and dissemination: The ACQUATIK study has
been approved by the NRES Committee West Midlands
—South Birmingham—Reference 13/WM/0317.
The results from ACQUATIK will be submitted for
publication in peer-reviewed journals and presented at
primary and secondary care conferences.
Trial registration number: ISRCTN37237454.
INTRODUCTION
Chronic kidney disease
Current deﬁnitions of chronic kidney disease
(CKD) use surrogates of kidney damage
(comprising at least one of: proteinuria,
abnormal urinary sediment, histological or
structural abnormality or history of a renal
transplant) and/or a glomerular ﬁltration
rate less than 60 mL/min/1.73 m2 present
on at least two occasions for 3 months or
more.1 2 The prevalence of early CKD is
increasing and now affects more than 13% of
the population in the developed world.3 This
increase has been largely driven by the
increasing prevalence of the most common
risk factors for CKD, including diabetes,
hypertension and older age.3 Among adults
aged more than 70 years, the prevalence of
CKD has been estimated to be more than
40% in the USA and UK.3 For an important
minority, CKD can progress to end-stage
renal disease (ESRD) requiring renal
replacement therapy (RRT) in the form of
Strengths and limitations of the study
▪ Novel research methodology facilitating patient
recruitment with minimal inconvenience to
patients and lower research costs.
▪ Large amounts of data available for analysis.
▪ Multicentre study recruiting from a large diverse
population increasing the generalisability of the
results.
▪ The observational nature of this study means
that causality cannot be attributed.
▪ The use of routinely collected patient data, rather
than data specifically collected as part of a
research study may result in more missing infor-
mation than would normally be expected.
▪ Patients who move away from England will be
lost to follow-up.
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either dialysis treatment or kidney transplantation.1 The
cost of CKD to the National Health Service (NHS) in
England in 2009–2010 has been estimated at £1.45
billion4; indirect costs may be far higher.5 The shift in
focus to active early detection and management of CKD,
and other chronic conditions, has become an increasing
priority for health services. Indeed, most patients with
CKD are now managed in the primary care setting with
little or no secondary care input.6 However, US data
demonstrates that patients with CKD are more likely to
be readmitted after a hospital admission than patients
without CKD,7 with the associated increase in costs and
comorbidity.
Cardiovascular risk and CKD
A recent large meta-analysis has conﬁrmed that for all
adults, including those aged 75 years or older, absolute
incidence rates of ESRD are substantially lower than
absolute mortality rates.8 The major cause of this
increased death rate has repeatedly been found to be
cardiovascular disease.8 Over a 1-year period (2009–
2010), approximately 7000 excess myocardial infarctions
and 12 000 excess strokes occurred in patients with CKD
in England compared to a non-CKD age and gender-
matched population.4 The cost to the NHS of these
extra events has been estimated at £178 million.4 This
does not take into account other cardiovascular events
such as sudden cardiac death or admissions for heart
failure, nor the costs to individual patients, carers or
society as a whole.
Outcomes for patients with CKD who suffer a myocar-
dial infarction or stroke are consistently reported as
worse than for patients without CKD.9 Studies in North
America and Europe have found that patients with CKD
are less likely to be treated with measures to prevent car-
diovascular disease, are less likely to receive evidence-
based treatments for a cardiovascular event when admit-
ted to hospital and are less likely to be discharged with
treatments aimed to prevent a further cardiovascular
event.10 11 There is emerging evidence that this is also
the case in the UK.12
Cardiovascular treatments in CKD
The low use of evidence-based treatments in patients
with CKD might partly account for the worse outcomes
in patients with CKD who sustain a cardiovascular
event.13 However, most cardiovascular treatments are
based on results from studies that have largely excluded
patients with moderate to severe CKD, advanced age or
multiple comorbidities.14 Furthermore, those trials that
did include elderly and patients with CKD had high
rates of patient withdrawal and early discontinuation of
therapy.15 To complicate matters further, there is increas-
ing evidence that patients with CKD may not beneﬁt as
much as patients without CKD from treatments for car-
diovascular disease and also have an increased risk of
suffering harm as a consequence.16 One example is the
paradox of both an increased thrombotic tendency and
an increased bleeding risk in patients with CKD and
comorbidity of atrial ﬁbrillation (AF).17 Another
example was identiﬁed in a recent meta-analysis that sug-
gested that the beneﬁts of antiplatelet therapy in
patients with CKD after an acute coronary syndrome are
unresolved and are potentially overshadowed by an
increased bleeding risk.18 Statins reduce atherosclerotic
events in patients with CKD to a similar degree to the
general population but reduce cardiovascular and total
mortality by a substantially smaller amount.19
Thus, applying treatment strategies that are proven
effective for the primary and secondary prevention of car-
diovascular disease in patients without CKD to patients
with CKD is challenging because of the lack of evidence
of efﬁcacy and the potential to do harm.20 Clinicians
increasingly recognise that some treatments proven to be
effective among middle-aged adults with normal kidney
function may have different risks and beneﬁts among
older patients with CKD and multiple comorbidities.16
Explanatory trials often select narrow ranges of
patients based on age, sex, comorbidity and concomitant
treatments and then monitor patients carefully. In con-
trast, patients in routine clinical practice are more
diverse, with varying disease histories and comedications
with different levels of compliance and adherence. In
fact, most explanatory studies exclude ‘average’ patients
who will end up receiving the intervention tested in the
trial.21 Furthermore, randomised controlled trials
(RCTs) are not necessarily the best way of tackling
certain research questions, such as what is the cardiovas-
cular risk associated with CKD. Rigorous observational
studies might be better suited for these purposes and in
many situations produce comparable conclusions to
RCTs.22 This type of study includes participants with a
broader variety of disease severity and more comorbid-
ities than patients normally recruited into RCTs.23
Use of electronic health records in clinical research
Electronic information systems in healthcare are evolv-
ing and are increasingly used in routine clinical care,
with primary care at the forefront in the UK. The rich-
ness and completeness of data held in computerised
patient record systems has been increasing with time as
more information is being shared electronically between
different parts of the healthcare system and as paper-
based patient records are being replaced by electronic
patient records. For example, laboratory test results are
increasingly being communicated electronically and
loaded automatically into the electronic patient record.
Use of these computerised health records can facilitate
the conduct of trials as patients can be preidentiﬁed
and followed up using routinely collected clinical data.
The potential for using electronic health records to
facilitate trials was highlighted over 10 years ago24
although at that time there were still substantial deﬁcien-
cies in the routinely collected data, most of which have
now largely been overcome.
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The Acute Care QUAliTy in chronic Kidney disease
(ACQUATIK) study provides a platform for linkage of:
non-identiﬁable patient data from primary care derived
from the Quality Outcomes Framework (QOF);25 elec-
tronically held records in secondary care and long-term
outcomes from the Hospital Episode Statistics (HES)
database in secondary care; and the Ofﬁce of National
Statistics (ONS). This information will allow the study of
a complete patient journey through primary and second-
ary care, providing unequalled levels of information on
treatment and outcomes of patients with CKD. Deﬁning
how CKD, older age, ethnicity and concurrent
comorbidities modify the effectiveness and safety of
today’s common therapies will facilitate improvements in
care for this group of patients.
Other studies have recently used existing electronic
health record research databases to conduct clinical
trials.21 A feasibility trial is currently ongoing using the
USA Department of Veterans Affairs computerised
patient record system.26 ACQUATIK has several potential
advantages over these types of studies; in particular, the
methods and procedures being developed are poten-
tially exportable to most hospitals and certainly all
primary care practices throughout England, allowing for
every patient with any medical condition in the country
to be eligible for participation in a research study. The
unique methodology employed in ACQUATIK could
therefore provide a platform for future interventional
studies at the interface between primary and secondary
care in the UK, allowing the seamless acquisition of
large volumes of data at low cost.
METHODS AND ANALYSIS
Study design
The ACQUATIK study is a prospective, multicentre
observational study of patients in the UK with and
without CKD. Two main centres in Birmingham,
University Hospitals Birmingham NHS Foundation Trust
(UHBFT) and Heart of England NHS Foundation Trust
(HEFT) are undertaking this study. Each centre has a
high number of admissions and serves a large diverse
population.
Inclusion criteria
▸ Participant is an inpatient at either UHBFT or HEFT.
▸ Participant is willing and able to give informed
consent to participate in the study.
▸ Men or women, aged 18 years or more.
▸ Patient is registered with a general practitioner (GP)
in the two main Clinical Commissioning Groups
(CCGs—clinically led groups that include all GPs in
their geographical area) served by UHBFT and HEFT
(Birmingham South Central CCG and Birmingham
Crosscity CCG). Clinical Commissioning Groups were
set up in April 2013 arising as part of the reforms set
out in the Health and Social Care Act 2012 and
replaced primary care trusts.27
Exclusion criteria
To enhance inclusivity, there are only a few exclusion
criteria:
▸ Unable to give informed consent.
▸ On dialysis or with a working kidney transplant.
▸ Already under long-term follow-up by a renal team in
secondary care.
▸ Attended a renal clinic in secondary care in the pre-
ceding 12 months.
▸ Patients whom clinical staff responsible for their care
feel are inappropriate for enrolment into the study.
Study process
The study process is laid out in ﬁgure 1.
1. Hospital electronic records are automatically
searched for current inpatients who fulﬁl the study
entry criteria. Patients who are under local renal
follow-up or have attended a renal clinic in the pre-
ceding 12 months or who are not registered with a
GP in the two CCGs involved are excluded at this
stage.
Figure 1 ACQUATIK study design.
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2. Clinical staff responsible for the care of identiﬁed
patients are approached to ensure they are appropri-
ate for the study.
3. The research team approaches suitable patients.
Where possible an introduction will be made by a
member of the clinical team known to the patient. If
there is any doubt about the participant’s ability to
give informed consent, they are excluded.
4. The researcher verbally explains the study and
answers any questions the potential participant may
have. The voluntary nature of participation and the
ability to withdraw at any time is emphasised. As
part of the consent process the patient is also asked
to consent to the use of information held by the
NHS and records maintained by the Health and
Social Care Information Centre (HSCIC).28 The
patient is given as much time as needed to think
through their participation. After a suitable period,
the patient is consented to participate in the study.
Before consent, the researcher conﬁrms with the
participant that they have understood the patient
information sheet.
5. During this visit, the patient and a member of the
study team jointly ﬁll in a questionnaire including
demographic details, usual GP, lifestyle factors,
kidney disease diagnosis and admission medication.
6. Data from biochemistry and haematology laboratory
investigations are electronically collected including
creatinine, estimated glomerular ﬁltration rate, urea,
albumin, haemoglobin, sodium, potassium, bicarbon-
ate, phosphate, parathyroid hormone and cholesterol.
7. A letter is sent to the GP with a photocopy of the
consent form. The GP surgery is asked to insert a
Read code into the patient’s electronic health
record. This will be to register within the GP database
that the patient has consented to be a part of the
study and enables subsequent extraction of preadmis-
sion data based on the QOF and prescribed medica-
tion records. Once the study has ended or the
patient withdraws from the study, a second Read code
will be sent to the GP that will prevent any further
data extractions. The UK Terminology Centre has
provided these Read codes.
8. Preconstructed software already installed will auto-
matically migrate the prespeciﬁed data to the
Department of Informatics at UHBFT. All data will be
transferred within the NHS N3 Network and held in
a secure NHS hospital environment with strict restric-
tions on access and data reuse agreements.
Data sources to be used
In addition to information obtained from the patient
interview and electronic health records used during
routine care, the following data sets will be accessed:
Quality and Outcomes Framework (QOF)
This is a system for the performance management and
payment of GPs in the NHS. It was introduced as part of
the new general medical services contract in April
2004.29 Multiple clinical conditions are featured (see
table 1) and it is a requirement for GPs to keep a data-
base of all patients diagnosed. One example is CKD,
where GPs are required to record all patients with an
estimated glomerular ﬁltration rate of less than 60 mL/
min/1.73 m2 (stage 3 CKD or worse) on a practice regis-
ter. This CKD record contains details of most patients
labelled with CKD in the UK.30
Hospital Episode Statistics
Hospital Episodes Statistics (HES) is an administrative
data set that collates information on all patients admit-
ted to all NHS hospitals in England. Each admission
contains a primary diagnosis and up to 19 secondary
diagnoses (recorded using the standard system of
International Classiﬁcation of Diseases, 10th edition),
and up to 24 procedure ﬁelds. In addition to diagnostic
and procedural codes, the HES database31 also records
the Charlson comorbidity index. Derived from the sec-
ondary diagnoses codes, this is a marker of comorbidity
and was originally formulated to predict mortality.32 The
Carstairs index of deprivation is derived from the
patient’s postcode.33 As well as clinical information, each
HES record will also contain routine information about
the patient (eg, age, sex, ethnicity and postcode) and
the episode of care (eg, hospital name, emergency
admission, date of admission and discharge). All hospi-
tals in England are required to submit data to HES.
Office of National Statistics
All deaths in England must be notiﬁed by law and
recorded by the Ofﬁce for National Statistics (ONS).
Deaths during the study period, including date and
cause of death, will be derived through linkage between
HES records and death registry information via the
ONS. This improves mortality capture by including
deaths outside of hospitals.
Information from these three databases has been col-
lated by systems developed at one hospital (UHBFT)
and one CCG and these are being tested at a second
hospital (HEFT) and CCG. ACQUATIK aims to develop
systems that are potentially exportable to other hospitals
and CCGs in England and use these to conduct large
multicentre interventional trials covering wider geo-
graphical areas in the future.
OUTCOME MEASURES
Primary outcome
Hospital readmission rates in patients with and without
CKD.
Secondary outcomes
1. Hospital readmission rates for any cardiovascular
event (including acute myocardial infarction, angina,
coronary artery bypass graft surgery, percutaneous
coronary intervention, peripheral arterial disease,
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revascularisation or stroke) in patients with and
without CKD.
2. All-cause and cardiovascular mortality in patients
with and without CKD.
3. Treatment received before, during and after admis-
sion to hospital with a cardiovascular event by
patients with and without CKD.
4. The risk: beneﬁt ratio for primary and secondary pre-
vention of cardiovascular disease in patients with and
without CKD.
5. Attainment of standards in chronic disease manage-
ment in patients with and without CKD.
6. Rates, severity and risk factors for acute kidney injury
in patients with and without CKD.
7. The proportion of patients with biochemical evi-
dence of CKD not classiﬁed so by the GP.
All primary and secondary outcomes will be analysed
separately to investigate the inﬂuence of age, sex, ethni-
city, socioeconomic status, deprivation score and concur-
rent comorbidities (including diabetes mellitus) on
outcomes, treatment and classiﬁcations. Determination
of socioeconomic status will be based on the Index of
Multiple Deprivation model calculated at the local
level.34
Table 1 Quality and Outcomes Framework (QOF) chronic disease domains
QOF domain Point for analysis
Chronic kidney disease (CKD) Is the patient on the CKD register?
If so, was the last BP reading (in the preceding 12 months) 140/85 mm Hg or less?
If so, what was the last ACR (or PCR) in the preceding 12 months?
Atrial fibrillation (AF) Is the patient on the AF register?
If so, what is their CHADS2 score?
Is the patient treated with anticoagulation drug therapy or antiplatelet therapy?
Secondary prevention of
coronary heart disease (CHD)
Is the patient on the CHD register?
If so, what was the latest BP (within 12 months)?
If so, what was the last measured cholesterol (within 12 months)?
If so, has the patient received influenza vaccination in the previous 12 months?
If so, is the patient on aspirin, alternative antiplatelet agent or oral anticoagulant?
Heart failure (HF) Is the patient on the HF register?
If so, is the patient currently treated with an ACE-I or ARB?
If on ACE-I or ARB are they also treated with a β-blocker?
Hypertension (HYP) Is the patient on the hypertension register?
If so, has the BP measured in the preceding 9 months been less than 150/90 mm Hg?
Peripheral arterial disease (PAD) Is the patient on the PAD register?
If so, has the BP in the preceding 12 months been 150/90 mm Hg or less?
If so, has the total cholesterol measured in the preceding 12 months been 5 mmol/L or
less?
If so, is the patient taking aspirin or an alternative antiplatelet agent?
Stroke and transient ischaemic
attack (STIA)
Is the patient on the STIA register?
If so, is the last BP reading measured in the preceding 12 months 150/90 mm Hg or less?
If so, what was the last measured cholesterol (within 12 months)?
If so, was the last measured cholesterol (within 12 months) less than 5 mmol/L?
If so, has the patient received influenza vaccination in the previous 12 months?
If so, is the patient on an antiplatelet agent or oral anticoagulation?
Diabetes mellitus (DM) Is the patient on the DM register?
If so, is the last BP reading measured in the preceding 12 months 150/90 mm Hg or less?
If so, is the last BP reading measured in the preceding 12 months 140/80 mm Hg or less?
If so, was the last measured cholesterol (within 12 months) less than 5 mmol/L?
If so, was the IFCC-HbA1c less than 59 mmol/mol in the preceding 12 months?
If so, was the IFCC-HbA1c less than 64 mmol/mol in the preceding 12 months?
If so, was the IFCC-HbA1c less than 75 mmol/mol in the preceding 12 months?
If so, has the patient received influenza vaccination in the previous 12 months?
Hypothyroidism (THY) Is the patient on the THY register?
If so, have they had a thyroid function test recorded in the preceding 12 months?
Asthma (AST) Is the patient on the AST register?
Chronic obstructive pulmonary
disease (COPD)
Is the patient on the COPD register?
If so, what was the last measured (within 12 months) FEV1?
If so, has the patient received the influenza vaccination in the previous 12 months?
ACR, urinary albumin: creatinine ratio; ARB, angiotensin receptor blocker; BP, blood pressure; CHADS2, C, congestive cardiac failure, H,
hypertension (treated or untreated (BP ≥140/90 mm Hg), A, age ≥75 years, D, diabetes mellitus, 2, previous stroke, TIA or thromboembolism;
FEV1, forced expiratory volume in 1 second; IFCC-HbA1c, International Federation of Clinical Chemistry glycated haemoglobin.
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In the ACQUATIK study patients with renal disease
under secondary care nephrology follow-up have been
excluded. Therefore, the majority of diagnoses coded
within HES and primary care databases will include
common systemic conditions such as hypertension and
diabetes mellitus as the aetiology of CKD, rather than
primary renal glomerulonephritides which would invari-
ably be under secondary care follow-up in the UK.
Conditions such as diabetes mellitus will also be present
in the non-CKD group and will form part of the prespe-
ciﬁed analysis of comorbidities during data analysis.
Total hospital readmission rate was selected as the
primary end point rather than readmission for cardio-
vascular events for the following reasons. First,
ACQUATIK was powered on total readmission rate of
patients with and without CKD as this is the available
data. Second, hospital readmission rate is more a
robust measure than an admission for a cardiovascular
event—which would be regarded as a secondary classiﬁ-
cation and based on a single primary admission code—
especially if a patient presents with more than one con-
dition simultaneously. For example, an admission with
a hip-fracture would be coded as such and may not
necessarily reﬂect an underlying cardiovascular cause
such as a cardiac arrhythmia or iatrogenic hypotensive
episode. Third, ACQUATIK seeks to ascertain readmis-
sions as a result of complications of treatments for car-
diovascular disease, for example, gastrointestinal
haemorrhage following antiplatelet therapy for acute
myocardial infarction. These two admissions (hip-
fracture after a hypotensive episode and gastrointestinal
bleed with aspirin), although highly relevant to our
study, would not have formed part of our primary end
point. Finally, hospital readmission for any cause is
seen as a marker of quality of care.35 This is the main
aim of the ACQUATIK study.
Follow-up period and study end
The patient enrolment period is 2 years. Patients will be
followed until death, withdrawal from the study, or for a
maximum of 4 years, whatever comes ﬁrst. For patients
who died during follow-up, information about the
causes of death will be collected. For patients who wish
to stop participation in the study, the reason for with-
drawal will be registered. The end of the study will be
deﬁned as the end of long-term follow-up 2 years after
the last patient was recruited into the study. The data
generated from this study will be held in a secure, anon-
ymised database for 2 years after the study ends. The
database will then be archived for a total of 10 years as
per sponsor guidelines after the study ends to protect
the integrity and auditability of the research. However,
given the likelihood that this data will be of great value
for future research the Chief Investigator will be apply-
ing for permission to maintain the database, under the
relevant conditions, to the appropriate regulatory
bodies.
Number of patients
A minimum of 4000 patients will be recruited into the
study. The sample size calculations were based on the
following information. Approximately 40% of patients
admitted to hospital will have evidence of CKD (data
from 4 years of emergency admissions to Queen
Elizabeth Hospital). This is consistent with published
international data.36 From US Medicare data,7 patients
without CKD aged 66 and over have a readmission rate
of 82 per 1000-patient years whereas patients with CKD
have a readmission rate of 116 per 1000-patient years.
From US Marketscan data7 patients without CKD aged
50 to 64 have a readmission rate of 56 per 1000-patient
years whereas patients with CKD have a readmission rate
of 72 per 1000-patient years. Therefore, in a best case
scenario, patients admitted to hospital in Birmingham
have annual readmission rates similar to US Medicare
data. To detect a difference of 34 (116–82) readmissions
per 1000 patient-years with 92% power would require a
sample size of 2000 with an average of 2 years follow-up.
In a worst case scenario, patients admitted to hospital in
Birmingham have annual readmission rates similar to
US Marketscan data. To detect a difference of 16 (72–
56) readmissions per 1000 patient-years with 80% power
would require a sample size of 4000 with an average of
2 years follow-up.
ANALYSES
Normally distributed continuous data will be presented
as mean±SD with comparisons made using Student’s t
test or one-way analysis of variance. Non-normally distrib-
uted data will be presented as median (IQR) and ana-
lysed using the Kruskal-Wallis test. Categorical data will
be presented as count (percentage) and analysed using
the χ2 test. In multivariable analyses, variables found to
be signiﬁcantly associated with the outcome under inves-
tigation in the univariable analyses will be used. Logistic
regression analysis will be used to assess the relationship
between outcomes and parameters under investigation
and the results expressed as an OR with 95% CIs.
Time-to-event data analysis will be performed using the
Cox proportional hazards model and the results
expressed as HR with 95% CIs.
Standard methods will be used to handle missing data
after being assessed for extent and as to whether this is
due to random missingness and/or censoring.37 38
ETHICS AND DISSEMINATION
Ethics
The Chief Investigator will guarantee that the study is
conducted in accordance with the Declaration of
Helsinki and will ensure that all staff involved in the
study are appropriately trained in Good Clinical Practice
(GCP). All staff will adhere to Caldicott principles, GCP
and the Data Protection Act, 1998 ensuring patient con-
ﬁdentiality. If needed, the Chief Investigator will submit
and gain approval for all substantial amendments to the
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original approved documents. All participants are identi-
ﬁed on study documents by use of a unique study
number that cannot be used to identify individual parti-
cipants. All study documents, both electronic and paper,
containing participant information are held securely
and are only accessible to study staff and authorised per-
sonnel. All essential data transfer happen within the
secure NHS N3 Network.
All patient identiﬁable data will be held separately
from the information collected on the patient and will
be used only if a member of the research team needs to
recontact the patient for any potential follow-up study
(speciﬁc consent will be obtained from participants for
this purpose). Patient identity will not be revealed in
publications arising from the study.
The study is registered on the ISRCTN (International
Standard Randomised Control Trial Number) database
(ISRCTN37237454).
Dissemination
In accordance with the Research Governance Framework
for Health and Social Care and GCP, results will be appro-
priately published and publicised. The investigators will
be involved in reviewing all publications arising from the
study. The authors of such publications will acknowledge
that the study is funded through a National Institute for
Health Research (NIHR) Fellowship Grant awarded to
the Chief Investigator as well as a strategic funding award
from the West Midlands (formerly Birmingham and
Black Country) Comprehensive Local Research Network.
The results from this study will be important for both
primary and secondary care communities. The ﬁndings
will be presented at both primary and secondary care
academic meetings. It is anticipated that this study will
produce manuscripts suitable for submission to relevant
peer-reviewed journals. It is our intention, if at all pos-
sible, to publish in open access journals to encourage
widespread diffusion of our ﬁndings.
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